NDAORALTABLET
Approved
May 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 7h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDROPRES 25 is a fixed-dose combination tablet containing hydrochlorothiazide (a thiazide diuretic) and reserpine (a rauwolfia alkaloid antihypertensive) approved in 1974 for hypertension management. This dual-mechanism oral antihypertensive works by reducing fluid volume and peripheral vascular resistance. The combination targets patients requiring multi-drug blood pressure control.
LOE Approaching
This product is in late lifecycle decline with minimal commercial activity; team sizes and investment are likely reduced compared to modern antihypertensives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching loss-of-exclusivity status, HYDROPRES 25 represents a career risk rather than an opportunity. This product offers minimal skill development, no growth trajectory, and limited visibility in modern pharmaceutical portfolios.
Legacy Brand ManagerField Sales Representative
Worked on HYDROPRES 25 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.